drugset / Trial / NCT04528212
Fenofibrate Versus Curcumin in Type 2 Diabetic Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this study is to evaluate the effect of fenofibrate versus curcumin on glycemic status, lipids profile, hs-CRP, sirtuin-1 and fetuin-A in type 2 diabetic patients who are taking glimepiride.
Timeline
- Start
- 2020-11-01
- Primary completion
- 2021-11-30
- Completion
- 2021-12-01
Publications
- Results Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Z, Majeed M, Sahebkar A. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med. 2017 Aug;33:1-5. doi: 10.1016/j.ctim.2017.05.006. Epub 2017 May 29.
- Results Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: A systematic review and meta-analysis. PLoS One. 2019 Apr 23;14(4):e0215840. doi: 10.1371/journal.pone.0215840. eCollection 2019.
- Results Noureldein MH, Abd El-Razek RS, El-Hefnawy MH, El-Mesallamy HO. Fenofibrate reduces inflammation in obese patients with or without type 2 diabetes mellitus via sirtuin 1/fetuin A axis. Diabetes Res Clin Pract. 2015 Sep;109(3):513-20. doi: 10.1016/j.diabres.2015.05.043. Epub 2015 Jun 11.
- Nada EM, El-Gharbawy NM, Abbas H, Werida RH. Effect of adding fenofibrate versus curcumin to glimepiride in patients with type 2 diabetes: a randomized controlled trial. BMC Pharmacol Toxicol. 2025 Jun 6;26(1):119. doi: 10.1186/s40360-025-00950-y.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Curcumin | Small molecule | 1100 mg | Oral |
| Subject | Fenofibrate | Small molecule | 160 mg | Oral |
| Background | Black Pepper | Unknown | 5 mg | — |
| Background | Glimepiride | Small molecule | 4 mg | Oral |